Study of Sunitinib in Subjects With High Risk Renal Cell Carcinoma

NCT01070186 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped No participants were enrolled.

Conditions

Renal Cell Carcinoma

Interventions

DRUG: Sunitinib
OTHER: Tumor biopsy
PROCEDURE: Nephrectomy
OTHER: Biomarkers

Sponsor

Jonsson Comprehensive Cancer Center

Collaborators

[object Object]